MARKET

ITCI

ITCI

INTRA CELLULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.71
+0.28
+1.13%
After Hours: 24.71 +0.01 +0.02% 16:55 07/10 EDT
OPEN
24.64
PREV CLOSE
24.43
HIGH
25.03
LOW
24.23
VOLUME
586.60K
TURNOVER
--
52 WEEK HIGH
43.56
52 WEEK LOW
6.75
MARKET CAP
1.64B
P/E (TTM)
-8.9098
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ITCI stock price target is 45.25 with a high estimate of 70.00 and a low estimate of 32.00.

EPS

ITCI News

More
Do Options Traders Know Something About Intra-Cellular Therapies (ITCI) Stock We Don't?
Zacks · 5d ago
Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure
GlobeNewswire · 06/29 13:00
Intra-Cellular's ITI-214 shows positive action in heart failure study
Seeking Alpha - Article · 06/29 12:45
Intra-Cellular Therapies Announces Top-line Results From ITI-214 Phase I/II Study In Patients With Heart Failure
Study demonstrated inhibiting phosphodiesterase-1 with ITI-214 in patients with heart failure improved cardiac function by enhancing cardiac contractility and dilating systemic arteries without inducing abnormal heart
Benzinga · 06/29 12:18
The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week
Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel t
Benzinga · 06/28 18:25
Intra-Cellular Therapies (ITCI) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/25 15:13
Do Hedge Funds Love Intra-Cellular Therapies Inc (ITCI)?
In this article you are going to find out whether hedge funds think Intra-Cellular Therapies Inc (NASDAQ:ITCI) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there h
Insider Monkey · 06/24 01:08
Intra-Cellular (ITCI) Moves to Buy: Rationale Behind the Upgrade
Zacks · 06/23 17:00

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About ITCI

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).
More

Webull offers kinds of Intra-Cellular Therapies Inc stock information, including NASDAQ:ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ITCI stock methods without spending real money on the virtual paper trading platform.